SynLife Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $296K

  • Investors
  • 3

SynLife General Information

Description

Developer of a biotechnology platform designed to help develop synthetic minimal cells. The company's platform builds synthetic minimal cells bottom-up that contain a biochemical mix of proteins that can transcribe and translate genes and a DNA program, enabling medical researchers to detect low-abundance molecular markers and cells.

Contact Information

Website
www.synlifebio.com
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Corporate Office
  • One Kendall Square
  • Cambridge, MA
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • One Kendall Square
  • Cambridge, MA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SynLife Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 10-Sep-2021 $296K Completed Generating Revenue
2. Grant 01-Apr-2019 Completed Generating Revenue
1. Angel (individual) 27-Jul-2018 $700K $700K Completed Generating Revenue
To view SynLife’s complete valuation and funding history, request access »

SynLife Patents

  • 13

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

SynLife Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3162786-A1 Microparticle-based enzyme systems for selective removal of target molecules Pending 09-Jan-2020
EP-4087598-A1 Microparticle-based enzyme systems for selective removal of target molecules Pending 09-Jan-2020
EP-4087598-A4 Microparticle-based enzyme systems for selective removal of target molecules Pending 09-Jan-2020
US-11723958-B2 Microparticle-based enzyme systems for selective removal of target molecules Active 09-Jan-2020
US-20210213107-A1 Microparticle-based enzyme systems for selective removal of target molecules Active 09-Jan-2020 A61K9/127
To view SynLife’s complete patent history, request access »

SynLife Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SynLife Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institutes of Health Government
National Aeronautics and Space Administration Government
Biological Engineering Ventures Venture Capital Minority
To view SynLife’s complete investors history, request access »

Ready to get started?

Request a free trial

SynLife FAQs

  • When was SynLife founded?

    SynLife was founded in 2017.

  • Where is SynLife headquartered?

    SynLife is headquartered in Cambridge, MA.

  • What is the size of SynLife?

    SynLife has 2 total employees.

  • What industry is SynLife in?

    SynLife’s primary industry is Drug Discovery.

  • Is SynLife a private or public company?

    SynLife is a Private company.

  • What is SynLife’s current revenue?

    The current revenue for SynLife is .

  • How much funding has SynLife raised over time?

    SynLife has raised $700K.

  • Who are SynLife’s investors?

    National Institutes of Health, National Aeronautics and Space Administration, and Biological Engineering Ventures have invested in SynLife.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process